RESMED INC | 2013 | FY |

(8)            Cost-Method Investments

 

The aggregate carrying amount of our cost-method investments at June 30, 2013 and June 30, 2012, was $4.0 million and $2.3 million, respectively.  During the year ended June 30, 2012 we remeasured a previously held equity interest to its acquisition date fair value as a result of acquiring the remaining interest as part of a business combination and recognized a gain of $2.1 million in other income, net within our consolidated statements of income. 

 

We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered.  We determine the fair value of our cost-method investments to evaluate whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values which can be market supported and unobservable inputs including future cash flows.  During the year ended June 30, 2013 and 2012, we recognized $0.5 million and $4.0 million, respectively, of impairment losses related to our cost-method investments. The expense associated with this impairment has been included in other income, net within our consolidated statements of income. We based these impairment losses on our determination that the declines in the fair value of these investments were other-than temporary.  We have determined, after the impairment charge, that the fair value of our remaining investments exceed their carrying values.

 

The following table shows a reconciliation of the changes in our cost-method investments during the years ended June 30, 2013 and June 30, 2012 (in thousands):